You are here: Industry Insights > Biocon

News List

Biocon board approves sale of branded formulations business to subsidiary expresspharma
June 21, 2019
Biocon will sell Branded Formulations India (BFI) business on a ‘going concern’ basis to its subsidiary Biocon Biologics India for Rs 45 crore.
Health Canada approves Biocon and Mylan’s Ogivri for cancer treatment expressbpd
May 30, 2019
Ogivri, used for the treatment of HER2-Positive breast and gastric cancers, is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan’s joint portfolio approved in the market
Biocon to soon expand its presence in biosimilars in US market expressbpd
April 04, 2019
Dr Mazumdar Shaw, CMD, Biocon said that women must be encouraged to become entrepreneurs
European Commission okays Mylan, Biocon’s biosimilar of cancer drug expressbpd
December 20, 2018
Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer
UK launch for Mylan, Biocon insulin glargine biosimilar Semglee pharmatimes
November 19, 2018
Mylan and Biocon have announced the UK launch of Semglee - an approved biosimilar of reference medicine insulin glargine.
Biocon: A nesting ground for biotech spinoffs biospectrumasia
October 12, 2018
Biocon: A nesting ground for biotech spinoffs
US OKs first biosimilar of Amgen's Neulasta pharmatimes
July 12, 2018
Mylan and Biocon's Fulphila has become the first biosimilar of Amgen's Neulasta to be approved by the US Food and Drug Administration.
Mylan and Biocon's Fulphila becomes first FDA-approved biosimilar of Amgen's Neulasta pharmafile
June 07, 2018
The FDA has granted approval to Mylan and Biocon’s Fulphila, the first biosimilar version of Amgen’s Neulasta (pegfilgrastim) to be approved in the US.
USFDA approves Mylan and Biocon’s Fulphila biospectrumasia
June 05, 2018
Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy.
Biocon sells 1.88 pc stake in Syngene for Rs 230 cr financialexpress
May 21, 2018
Biocon has sold close to 2 per cent stake in its research arm Syngene International for an estimated Rs 230 crore.

Previous page 1 2 3 4 5 6 Next page